Durata Therapeutics prices IPO at $9, below the range

By Renaissance Capital,

Shutterstock photo

Durata Therapeutics, which is developing a Phase 3 antibiotic candidate for acute skin infections, raised $68 million by offering 7.5 million shares at $9, below the range of $11 to $13. Because Durata had planned to offer only 6.3 million shares, the proceeds were just 9% less than expected. Durata Therapeutics plans to list on the NASDAQ under the symbol DRTX. BofA Merrill Lynch and Credit Suisse acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: DRTX

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com